GSK raises bet on AIDS drug with new Shionogi deal
LONDON/TOKYO (Reuters) - GlaxoSmithKline has raised its bet on a promising drug for HIV/AIDS by redrawing a deal with Japan's Shionogi which gives it a much bigger economic interest in the new product. Dolutegravir, a once-daily drug that has performed strongly in clinical trials, is seen by analysts as a potential multi-billion-dollar-a-year seller and a strong competitor to treatments from market leader Gilead Sciences. The drug belongs to a novel class known as integrase inhibitors that block the virus causing AIDS from entering cells. ...
Source: news.yahoo.com
No comments:
Post a Comment